SCHEMBL21980088

SCHEMBL21980088

CC(C)(C)Oc1ccc2cc(Br)ccc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.49
THRB P10828 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP2A6 P11509 1/20 0.35
TLR2 O60603 1/20 0.35
ALDH1A1 P00352 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
PSMB5 P28074 1/20 0.33
PABPC1 P11940 1/20 0.33
PPARA Q07869 1/20 0.32
PRNP P04156 1/20 0.32
TYMS P04818 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28905919 0.81 CYP1A2 (0.53) BACE1CYP2A6ALDH1A1CYP1A2KDM4E
SCHEMBL727654 0.80 BACE1 (0.53) BACE1L3MBTL1CYP2A6TLR2KDM4E
SCHEMBL12144961 0.76 BACE1 (0.42) BACE1THRBL3MBTL1TLR2ALDH1A1
SCHEMBL4278377 0.74 CYP1A2 (0.47) BACE1ALDH1A1CYP1A2KDM4EMEN1
SCHEMBL31754005 0.73 BACE1 (0.46) BACE1THRBL3MBTL1CYP2A6TLR2
SCHEMBL13196951 0.73 BACE1 (0.40) BACE1THRBL3MBTL1TLR2MEN1
SCHEMBL1161750 0.73 KCNH2 (0.40) BACE1MAPT
SCHEMBL1161752 0.73 KCNH2 (0.40) BACE1MAPT
SCHEMBL27259576 0.73 F2 (0.41) BACE1THRBL3MBTL1CYP2A6ALDH1A1
SCHEMBL10220222 0.73 BACE1 (0.53) BACE1CYP2A6TLR2ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384789-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
CN-111065626-B Compounds for the treatment of huntington's disease PTC医疗公司 2024-09-27 CN disclosed
EP-3634953-B1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2024-01-03 EP disclosed
EP-4151627-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2023-03-22 EP disclosed
US-20220251098-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2022-08-11 US disclosed
US-11407753-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2022-08-09 US disclosed
US-20200165256-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2020-05-28 US disclosed
CN-111065626-A Compounds for the treatment of huntington's chorea PTC医疗公司 2020-04-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251098-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH BACE1 486/4885THRB 2497/4885L3MBTL1 3944/4885
US-20200165256-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH BACE1 486/4885THRB 2497/4885L3MBTL1 3944/4885
US-11407753-B2 Compounds for treating Huntington's disease HTT, HYPK, FH BACE1 486/4885THRB 2497/4885L3MBTL1 3944/4885
US-12384789-B2 Compounds for treating Huntington's disease HTT, HYPK, FH BACE1 486/4885THRB 2497/4885L3MBTL1 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.